

ESTTA Tracking number: **ESTTA721948**

Filing date: **01/21/2016**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	91211414
Party	Defendant Purepharma ApS
Correspondence Address	CARLA C CALCAGNO CALCAGNO LAW PLLC 1250 24TH ST NW STE 300 WASHINGTON, DC 20037 UNITED STATES cccalcagno@gmail.com
Submission	Other Motions/Papers
Filer's Name	Carla C. Calcagno
Filer's e-mail	cccalcagno@gmail.com,trademarks@canopyparalegal.com
Signature	/Carla C. Calcagno/
Date	01/21/2016
Attachments	PuraPharm v Purepharma Response to Status Request 1.21.16.pdf(27300 bytes )

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

PURAPHARM INTERNATIONAL (H.K.)  
LIMITED,

Opposer,

v.

PUREPHARMA APS,

Applicant.

Opposition No. 91211414

**PUREPHARMA'S RESPONSE TO BOARD REQUEST FOR STATUS REPORT**

Pursuant to the Board's Order dated December 22, 2015, Applicant PurePharma APS ("PurePharma"), files the present report on the status of the pending civil action.

1. On February 25, 2015, Purepharma filed a Motion to Transfer the pending Civil Action from the United States District Court, Southern District of Texas, Houston Division, to the United States District Court, Northern District of California, San Francisco Division.

2. The Court granted Purepharma's Motion and the case was thereafter transferred to the Northern District of California, and is now the subject of an action styled *PuraPharm International (H.K.) Limited v. PurePharma, Inc. and PurePharma APS*, Civil Action No. 315-cv-01808-JSC.

3. Pursuant to that Court's Order Setting Initial Case Management Conference and ADR Deadlines, the parties participated in private mediation on November 20, 2015.

4. It is the undersigned counsel's understanding that as a result of the mediation, the parties reached a settlement in principal. The parties are now working to finalize the formal

written settlement agreement, which, if signed, should dispose of the Opposition as well as the pending Civil Action.

5. As this settlement, if signed, should dispose of the Opposition and the Civil Action, Applicant respectfully requests that the Board continue to suspend the opposition until the settlement agreement has been signed and the civil action concluded.

Respectfully submitted,

/Carla C. Calcagno/

Carla Calcagno, Esq.

Janet Ricciuti, Esq.

Calcagno Law PLLC

1250 24<sup>th</sup> Street, N.W., Suite 300

Washington, D.C. 20037,

Carla.calcagno@calcagnolaw.com

[cccagno@gmail.com](mailto:cccagno@gmail.com)

202 466-0544

*Attorneys for Applicant PurePharma APS*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that on January 21, 2016 a true and accurate copy of the foregoing:

PUREPHARMA'S RESPONSE TO BOARD REQUEST FOR STATUS REPORT  
was served by agreement of the parties on Opposer by emailing a copy of the same to Melissa S. Rizzo, Attorney for Opposer, at [melissa.rizzo@arlaw.com](mailto:melissa.rizzo@arlaw.com) and [trademarks@arlaw.com](mailto:trademarks@arlaw.com).

*/Carla Calcagno/*